Expression of CD9 and CD82 in clear cell renal cell carcinoma and its clinical significance

Hyeongju Kwon, Sun Young Min, Min Jee Park, Cheol Lee, Jeong Hwan Park, Ji Youn Chae, Kyung Chul Moon

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

CD9 and CD82, members of the tetraspanin family, act as metastasis suppressors in many human malignant tumors, but the role of these molecules is not well known in clear cell renal cell carcinoma (CCRCC). This study was designed to evaluate the immunohistochemical expression of CD9 and CD82 in 644 cases of CCRCC and to determine the clinicopathologic and prognostic significance of their expression. The percentage of positive tumor cells was evaluated, and the expression was classified into 2 categories: low expression (less than 10% positive cells) or high expression (more than 10% positive cells) for CD9 expression and negative (no positive cells) or positive for CD82 expression. CD9 high expression was found in 303 (47.0%) patients, and CD82 positivity was found in 98 (15.2%) patients. High expression of CD9 was statistically associated with older patients (p= 0.003). The cases showing positive immunoreactivity for CD82 exhibited a high stage (p<. 0.001) and high nuclear grade (p<. 0.001). The overall, cancer-specific and progression-free survival rates were significantly higher in patients with a CD82-negative profile compared to patients with a CD82-positive profile (p<. 0.001). Although the biological function of CD82 in CCRCC remains unclear, the CCRCC patients with CD82 positive expression show poor prognosis.

Original languageEnglish
Pages (from-to)285-290
Number of pages6
JournalPathology Research and Practice
Volume210
Issue number5
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Renal Cell Carcinoma
Neoplasms
Disease-Free Survival
Survival Rate
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Cell Biology

Cite this

Kwon, Hyeongju ; Min, Sun Young ; Park, Min Jee ; Lee, Cheol ; Park, Jeong Hwan ; Chae, Ji Youn ; Moon, Kyung Chul. / Expression of CD9 and CD82 in clear cell renal cell carcinoma and its clinical significance. In: Pathology Research and Practice. 2014 ; Vol. 210, No. 5. pp. 285-290.
@article{29935cbd40954210a3a17581eeb25456,
title = "Expression of CD9 and CD82 in clear cell renal cell carcinoma and its clinical significance",
abstract = "CD9 and CD82, members of the tetraspanin family, act as metastasis suppressors in many human malignant tumors, but the role of these molecules is not well known in clear cell renal cell carcinoma (CCRCC). This study was designed to evaluate the immunohistochemical expression of CD9 and CD82 in 644 cases of CCRCC and to determine the clinicopathologic and prognostic significance of their expression. The percentage of positive tumor cells was evaluated, and the expression was classified into 2 categories: low expression (less than 10{\%} positive cells) or high expression (more than 10{\%} positive cells) for CD9 expression and negative (no positive cells) or positive for CD82 expression. CD9 high expression was found in 303 (47.0{\%}) patients, and CD82 positivity was found in 98 (15.2{\%}) patients. High expression of CD9 was statistically associated with older patients (p= 0.003). The cases showing positive immunoreactivity for CD82 exhibited a high stage (p<. 0.001) and high nuclear grade (p<. 0.001). The overall, cancer-specific and progression-free survival rates were significantly higher in patients with a CD82-negative profile compared to patients with a CD82-positive profile (p<. 0.001). Although the biological function of CD82 in CCRCC remains unclear, the CCRCC patients with CD82 positive expression show poor prognosis.",
author = "Hyeongju Kwon and Min, {Sun Young} and Park, {Min Jee} and Cheol Lee and Park, {Jeong Hwan} and Chae, {Ji Youn} and Moon, {Kyung Chul}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.prp.2014.01.004",
language = "English",
volume = "210",
pages = "285--290",
journal = "Pathology Research and Practice",
issn = "0344-0338",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "5",

}

Expression of CD9 and CD82 in clear cell renal cell carcinoma and its clinical significance. / Kwon, Hyeongju; Min, Sun Young; Park, Min Jee; Lee, Cheol; Park, Jeong Hwan; Chae, Ji Youn; Moon, Kyung Chul.

In: Pathology Research and Practice, Vol. 210, No. 5, 01.01.2014, p. 285-290.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of CD9 and CD82 in clear cell renal cell carcinoma and its clinical significance

AU - Kwon, Hyeongju

AU - Min, Sun Young

AU - Park, Min Jee

AU - Lee, Cheol

AU - Park, Jeong Hwan

AU - Chae, Ji Youn

AU - Moon, Kyung Chul

PY - 2014/1/1

Y1 - 2014/1/1

N2 - CD9 and CD82, members of the tetraspanin family, act as metastasis suppressors in many human malignant tumors, but the role of these molecules is not well known in clear cell renal cell carcinoma (CCRCC). This study was designed to evaluate the immunohistochemical expression of CD9 and CD82 in 644 cases of CCRCC and to determine the clinicopathologic and prognostic significance of their expression. The percentage of positive tumor cells was evaluated, and the expression was classified into 2 categories: low expression (less than 10% positive cells) or high expression (more than 10% positive cells) for CD9 expression and negative (no positive cells) or positive for CD82 expression. CD9 high expression was found in 303 (47.0%) patients, and CD82 positivity was found in 98 (15.2%) patients. High expression of CD9 was statistically associated with older patients (p= 0.003). The cases showing positive immunoreactivity for CD82 exhibited a high stage (p<. 0.001) and high nuclear grade (p<. 0.001). The overall, cancer-specific and progression-free survival rates were significantly higher in patients with a CD82-negative profile compared to patients with a CD82-positive profile (p<. 0.001). Although the biological function of CD82 in CCRCC remains unclear, the CCRCC patients with CD82 positive expression show poor prognosis.

AB - CD9 and CD82, members of the tetraspanin family, act as metastasis suppressors in many human malignant tumors, but the role of these molecules is not well known in clear cell renal cell carcinoma (CCRCC). This study was designed to evaluate the immunohistochemical expression of CD9 and CD82 in 644 cases of CCRCC and to determine the clinicopathologic and prognostic significance of their expression. The percentage of positive tumor cells was evaluated, and the expression was classified into 2 categories: low expression (less than 10% positive cells) or high expression (more than 10% positive cells) for CD9 expression and negative (no positive cells) or positive for CD82 expression. CD9 high expression was found in 303 (47.0%) patients, and CD82 positivity was found in 98 (15.2%) patients. High expression of CD9 was statistically associated with older patients (p= 0.003). The cases showing positive immunoreactivity for CD82 exhibited a high stage (p<. 0.001) and high nuclear grade (p<. 0.001). The overall, cancer-specific and progression-free survival rates were significantly higher in patients with a CD82-negative profile compared to patients with a CD82-positive profile (p<. 0.001). Although the biological function of CD82 in CCRCC remains unclear, the CCRCC patients with CD82 positive expression show poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84898058665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898058665&partnerID=8YFLogxK

U2 - 10.1016/j.prp.2014.01.004

DO - 10.1016/j.prp.2014.01.004

M3 - Article

C2 - 24553302

AN - SCOPUS:84898058665

VL - 210

SP - 285

EP - 290

JO - Pathology Research and Practice

JF - Pathology Research and Practice

SN - 0344-0338

IS - 5

ER -